155 related articles for article (PubMed ID: 33588087)
1. A Phase 2b randomized trial of lorecivivint, a novel intra-articular CLK2/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis.
Yazici Y; McAlindon TE; Gibofsky A; Lane NE; Lattermann C; Skrepnik N; Swearingen CJ; Simsek I; Ghandehari H; DiFrancesco A; Gibbs J; Tambiah JRS; Hochberg MC
Osteoarthritis Cartilage; 2021 May; 29(5):654-666. PubMed ID: 33588087
[TBL] [Abstract][Full Text] [Related]
2. Lorecivivint, a Novel Intraarticular CDC-like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Yazici Y; McAlindon TE; Gibofsky A; Lane NE; Clauw D; Jones M; Bergfeld J; Swearingen CJ; DiFrancesco A; Simsek I; Tambiah J; Hochberg MC
Arthritis Rheumatol; 2020 Oct; 72(10):1694-1706. PubMed ID: 32432388
[TBL] [Abstract][Full Text] [Related]
3. Individual Participant Symptom Responses to Intra-Articular Lorecivivint in Knee Osteoarthritis: Post Hoc Analysis of a Phase 2B Trial.
Tambiah JRS; Kennedy S; Swearingen CJ; Simsek I; Yazici Y; Farr J; Conaghan PG
Rheumatol Ther; 2021 Jun; 8(2):973-985. PubMed ID: 34101138
[TBL] [Abstract][Full Text] [Related]
4. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study.
Yazici Y; McAlindon TE; Fleischmann R; Gibofsky A; Lane NE; Kivitz AJ; Skrepnik N; Armas E; Swearingen CJ; DiFrancesco A; Tambiah JRS; Hood J; Hochberg MC
Osteoarthritis Cartilage; 2017 Oct; 25(10):1598-1606. PubMed ID: 28711582
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Deshmukh V; O'Green AL; Bossard C; Seo T; Lamangan L; Ibanez M; Ghias A; Lai C; Do L; Cho S; Cahiwat J; Chiu K; Pedraza M; Anderson S; Harris R; Dellamary L; Kc S; Barroga C; Melchior B; Tam B; Kennedy S; Tambiah J; Hood J; Yazici Y
Osteoarthritis Cartilage; 2019 Sep; 27(9):1347-1360. PubMed ID: 31132406
[TBL] [Abstract][Full Text] [Related]
6. Comparing Patient-Reported Outcomes From Sham and Saline-Based Placebo Injections for Knee Osteoarthritis: Data From a Randomized Clinical Trial of Lorecivivint.
Tambiah JRS; Simsek I; Swearingen CJ; Kennedy S; Cole BJ; McAlindon TE; Yazici Y
Am J Sports Med; 2022 Mar; 50(3):630-636. PubMed ID: 35005990
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of intra-articular injection of tropomyosin receptor kinase A inhibitor in painful knee osteoarthritis: a randomized, double-blind and placebo-controlled study.
Krupka E; Jiang GL; Jan C
Osteoarthritis Cartilage; 2019 Nov; 27(11):1599-1607. PubMed ID: 31351965
[TBL] [Abstract][Full Text] [Related]
8. Lorecivivint, an intra-articular potential disease-modifying osteoarthritis drug.
Sabha M; Siaton BC; Hochberg MC
Expert Opin Investig Drugs; 2020 Dec; 29(12):1339-1346. PubMed ID: 33096010
[No Abstract] [Full Text] [Related]
9. Safety, Tolerability, and Pharmacokinetics of Same-Knee Intra-Articular Injection of Corticosteroid and Lorecivivint Within 7 Days: An Open-Label, Randomized, Parallel-Arm Study.
Fineman MS; McAlindon TE; Lattermann C; Swearingen CJ; Kennedy S; Lopez VA; Simsek I; Tambiah JRS; Yazici Y
Rheumatol Ther; 2023 Dec; 10(6):1741-1752. PubMed ID: 37902943
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis.
Langworthy MJ; Conaghan PG; Ruane JJ; Kivitz AJ; Lufkin J; Cinar A; Kelley SD
Adv Ther; 2019 Jun; 36(6):1398-1411. PubMed ID: 30968336
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of intra-articular lidocaine administration in chronic knee pain due to osteoarthritis: A randomized, double-blind, controlled study.
Eker HE; Cok OY; Aribogan A; Arslan G
Anaesth Crit Care Pain Med; 2017 Apr; 36(2):109-114. PubMed ID: 27485803
[TBL] [Abstract][Full Text] [Related]
12. Single intra-articular injection of lightly cross-linked hyaluronic acid reduces knee pain in symptomatic knee osteoarthritis: a multicenter, double-blind, randomized, placebo-controlled trial.
Petterson SC; Plancher KD
Knee Surg Sports Traumatol Arthrosc; 2019 Jun; 27(6):1992-2002. PubMed ID: 30159738
[TBL] [Abstract][Full Text] [Related]
13. Effect of Tanezumab on Joint Pain, Physical Function, and Patient Global Assessment of Osteoarthritis Among Patients With Osteoarthritis of the Hip or Knee: A Randomized Clinical Trial.
Schnitzer TJ; Easton R; Pang S; Levinson DJ; Pixton G; Viktrup L; Davignon I; Brown MT; West CR; Verburg KM
JAMA; 2019 Jul; 322(1):37-48. PubMed ID: 31265100
[TBL] [Abstract][Full Text] [Related]
14. Hyaluronic Acid Versus Platelet-Rich Plasma: A Prospective, Double-Blind Randomized Controlled Trial Comparing Clinical Outcomes and Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis.
Cole BJ; Karas V; Hussey K; Pilz K; Fortier LA
Am J Sports Med; 2017 Feb; 45(2):339-346. PubMed ID: 28146403
[TBL] [Abstract][Full Text] [Related]
15. Corticosteroid compared with hyaluronic acid injections for the treatment of osteoarthritis of the knee. A prospective, randomized trial.
Leopold SS; Redd BB; Warme WJ; Wehrle PA; Pettis PD; Shott S
J Bone Joint Surg Am; 2003 Jul; 85(7):1197-203. PubMed ID: 12851342
[TBL] [Abstract][Full Text] [Related]
16. A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-200, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee.
Strand V; Baraf HSB; Lavin PT; Lim S; Hosokawa H
Osteoarthritis Cartilage; 2012 May; 20(5):350-356. PubMed ID: 22342928
[TBL] [Abstract][Full Text] [Related]
17. A prospective, randomized, double-blind, placebo controlled study to evaluate the efficacy of intraarticular hyaluronic acid for osteoarthritis of the knee.
Petrella RJ; Petrella M
J Rheumatol; 2006 May; 33(5):951-6. PubMed ID: 16652426
[TBL] [Abstract][Full Text] [Related]
18. A small-molecule inhibitor of the Wnt pathway, lorecivivint (SM04690), as a potential disease-modifying agent for the treatment of degenerative disc disease.
Deshmukh V; Ibanez M; Hu H; Cahiwat J; Wei Y; Stewart J; Hood J; Yazici Y
Spine J; 2020 Sep; 20(9):1492-1502. PubMed ID: 32413487
[TBL] [Abstract][Full Text] [Related]
19. A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
Kivitz A; Ma C; Ahdieh H; Galer BS
Clin Ther; 2006 Mar; 28(3):352-64. PubMed ID: 16750450
[TBL] [Abstract][Full Text] [Related]
20. Comparison between intra-articular ozone and placebo in the treatment of knee osteoarthritis: A randomized, double-blinded, placebo-controlled study.
Lopes de Jesus CC; Dos Santos FC; de Jesus LMOB; Monteiro I; Sant'Ana MSSC; Trevisani VFM
PLoS One; 2017; 12(7):e0179185. PubMed ID: 28738079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
